trebananib
Small moleculeexperimental
Clinical trial activity
37 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
22
Phase 3
5
Phase 4
0
Earliest trial started Feb 3, 2005 (NCT00102830)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Central Nervous System Neoplasms · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 3
- Fractures, Bone · Phase 3
- Fractures, Stress · Phase 3
- Gastrointestinal Neoplasms · Phase 2
- General Surgery · Phase 3
- Genital Neoplasms, Female · Phase 1
- Glioblastoma · Phase 2
- Gliosarcoma · Phase 2
- Hamartoma · Phase 3
- Hemangiosarcoma · Phase 2
- Kidney Diseases · Phase 1
- Kidney Failure, Chronic · Phase 1
- Leukemia, Monocytic, Acute · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Acute · Phase 1
- Lung Neoplasms · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroendocrine Tumors · Phase 1
- Oligodendroglioma · Phase 2
- Ovarian Neoplasms · Phase 3
- Pain · Phase 3
- Prostatic Neoplasms · Phase 2
- Rectal Neoplasms · Phase 2
- Sarcoma · Phase 2
- Sprains and Strains · Phase 3
- Tendinopathy · Phase 3
- Uterine Neoplasms · Phase 2
Mechanism of action
- Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
Inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor.
- Angiopoietin-1INHIBITOR
ANGPT1 inhibitor
Inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108568 ↗
Also known as
- amg386
- amg386
- amg 386
- amg 386
- amg 386
- amg-386
- amg-386
- amg-386
- natrium
- natrium
- sodium
- sodium
- tovasanib
- trebananib
- trebananib
- trebananib
- trebananib
- trenananib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02525835 | N/A | Dec 1, 2017 | Vanderbilt University |
| NCT03239145 | Phase 1 | Aug 31, 2017 | Amgen, Harvard University, Merck |
| NCT02346786 | Phase 3 | Apr 1, 2015 | Centre de Recherche Rhumatologique et Thermal |
| NCT01907308 | Phase 2 | Feb 1, 2014 | Amgen, University of Colorado, Denver |
| NCT01828138 | N/A | May 1, 2013 | Lundbeck, The Danish Council for Strategic Research, University of Southern Denmark |
| NCT01666977 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Amgen |
| NCT01664182 | Phase 2 | Aug 1, 2012 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01992341 | Phase 1 | Jul 1, 2012 | Amgen |
| NCT01623869 | Phase 2 | Jul 1, 2012 | National Cancer Institute (NCI) |
| NCT01609790 | Phase 2 | Jun 1, 2012 | National Cancer Institute (NCI), NRG Oncology |
| NCT01548482 | Phase 1 | Mar 1, 2012 | National Cancer Institute (NCI), University of Toronto |
| NCT01553188 | Phase 2 | Feb 7, 2012 | National Cancer Institute (NCI) |
| NCT01538095 | Phase 1 | Feb 1, 2012 | National Cancer Institute (NCI) |
| NCT01493505 | Phase 3 | Jan 1, 2012 | Amgen |
| NCT01563367 | Phase 3 | Jan 1, 2012 | Pharmacosmos |
| NCT01555268 | Phase 1 | Oct 31, 2011 | Amgen, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01331941 | Phase 1 | Sep 1, 2011 | Amgen |
| NCT01210222 | Phase 2 | Jun 1, 2011 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT01281254 | Phase 3 | Apr 18, 2011 | Amgen |
| NCT01290263 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2010 | Amgen, Harvard University |
Showing 20 of 37 trials
Page 1 / 2
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 22 | 18 | 3 | 2005 |
| National Cancer Institute (NCI) | Government | 8 | 6 | 2 | 2011 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2010 |
| NRG Oncology | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Austin Health | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Centre de Recherche Rhumatologique et Thermal | Academic/Hospital | 1 | 1 | 1 | 2015 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Gynecologic Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Lundbeck | For profit | 1 | 0 | 1 | 2013 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| Pharmacosmos | For profit | 1 | 1 | 1 | 2012 |
| QuantumLeap Healthcare Collaborative | Academic/Hospital | 1 | 1 | 1 | 2010 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Takeda | For profit | 1 | 1 | 1 | 2009 |
| Telemark Hospital Trust | Academic/Hospital | 1 | 1 | 1 | 2007 |
| The Danish Council for Strategic Research | Government | 1 | 0 | 1 | 2013 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Southern Denmark | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2012 |
21 organizations
Page 1 / 2